Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1551-1557

  Rajkumar, S Vincent ^a   Fonseca, Rafael ^a   Lacy, Martha Q ^a   Witzig, Thomas E ^a   Therneau, Terry M ^a   Kyle, Robert A ^a   Litzow, Mark R ^a   Gertz, Morie A ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER RECURRENCE; CELL STRUCTURE; CHROMOSOME ABERRATION; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 0032945928     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1551     Document Type: Article

References (25)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997
2. Bataille R, Harousseau JL: Multiple myeloma. N Engl J Med 336:1657-1664, 1997
3. Kyle RA: Long-term survival in multiple myeloma. N Engl J Med 308:314-316, 1983
4. Harousseau JL, Attal M: The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 34:61-66, 1997
5. Barlogie B, Hall R, Zander A, et al: High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298-1301, 1986
6. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
7. Waldron J, Jazieh R, Jagannath S, et al: Bone marrow morphology (BMM) adds critical prognostic information to other standard parameters (SP) including cytogenetics among newly diagnosed multiple myeloma (MM) patients (PTS) receiving total therapy (TT). Blood 90:90a, 1997 (suppl 1, abstr 394)
8. Greipp PR, Raymond NM, Kyle RA, et al: Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood 65:305-310, 1985
9. Greipp PR, Lust JA, WM OF, et al: Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382-3387, 1993
10. Bartl R, Frisch B, Burkhardt R, et al: Bone marrow histology in myeloma: Its importance in diagnosis, prognosis, classification and staging. Br J Haematol 51:361-375, 1982
11. Carter A, Hocherman I, Linn S, et al: Prognostic significance of plasma cell morphology in multiple myeloma. Cancer 60:1060-1065, 1987
12. Paule B, Quillard J, Bisson M, et al: Prognostic significance of plasma cell morphology in multiple myeloma. Nouv Rev Fr Hematol 30:209-212, 1988
13. Greipp PR, Leong T, Bennett JM, et al: Plasmablastic morphology: An independent prognostic factor with clinical and laboratory correlates - Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 91:2501-2507, 1998
14. Witzig TE, Gonchoroff NJ, Katzmann JA, et al: Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol 6:1041-1046, 1988
15. Mitelman F: ISCN (1995): An International System for Human Cytogenetics Nomenclature. Basel, Switzerland, S. Karger, 1995
16. Spurbeck JL, Carlson RO, Allen JE, et al: Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genet Cytogenet 32:59-66, 1988
17. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34:187-202, 1972
19. Kyle RA: Prognostic factors in multiple myeloma. Stem Cells 2:56-63, 1995
20. Liu P, Leong T, Quam L, et al: Activating mutations of N-and K.-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88:2699-2706, 1996
21. Tricot G, Sawyer JR, Jagannath S, et al: Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15:2659-2666, 1997
22. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 330:484-489, 1994
23. Attal M, Harousseau JL: Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 11:133-146, 1997
24. Alexanian R, Dimopoulos M, Smith T, et al: Limited value of myeloablative therapy for late multiple myeloma. Blood 83:512-516, 1994
25. Fermand JP, Ravaud P, Chevret S, et al: Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): Results of a prospective randomized trial. Blood 88:685a, 1996 (suppl 1, abstr 2730)